article Open AccessTop 1% cited
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Annals of Oncology · 2016 · Vol. 28(1) · pp. 16–33
Fátima Cardoso✉A. Costa(European School of Oncology)Elżbieta Senkus(Gdańsk Medical University)Matti Aapro(Breast Center)Fabrice André(Institut Gustave Roussy)Carlos H. Barrios(Pontifícia Universidade Católica do Rio Grande do Sul)Jonas Bergh(Karolinska Institutet)G.S. Bhattacharyya(Fortis Hospital)Laura Biganzoli(Hospital of Prato)Maria João Cardoso(Champalimaud Foundation)L. Carey(UNC Lineberger Comprehensive Cancer Center)D. Corneliussen-James(METAvivor)Giuseppe Curigliano(European Institute of Oncology)Véronique Dièras(Institut Curie)N. El Saghir(American University of Beirut)Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta)Lesley Fallowfield(Brighton and Sussex Medical School)D. FenechPrudence A. Francis(Peter MacCallum Cancer Centre)Karen A. Gelmon(BC Cancer Agency)Alessandra Gennari(Ente Ospedaliero Ospedali Galliera)Nadia HarbeckClifford A. Hudis(Memorial Sloan Kettering Cancer Center)Bella Kaufman(Sheba Medical Center)Ian E. Krop(Dana-Farber Cancer Institute)Musa MayerHanneke Meijer(Radboud University Nijmegen)Shirley Mertz(Metastatic Breast Cancer Network)Shinji Ohno(The Cancer Institute Hospital)Olivia Pagani(Institute of Oncology Research)Efthymios Papadopoulos(European University Cyprus)Fedro A. Peccatori(European School of Oncology)Frédérique Penault‐Llorca(Centre Jean Perrin)Martine Piccart(Institut Jules Bordet)Jean‐Yves Pierga(Délégation Paris 5)Hope S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center)Lillie D. Shockney(Breast Center)George W. Sledge(Indiana University – Purdue University Indianapolis)Sandra M. Swain(Georgetown University Medical Center)Christoph Thomssen(Martin Luther University Halle-Wittenberg)Andrew Tutt(Guy's and St Thomas' NHS Foundation Trust)Daniel Vorobiof(The Medical Oncology Centre of Rosebank)Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)Larry Norton(Memorial Sloan Kettering Cancer Center)Eric P. Winer(Dana-Farber Cancer Institute)
Abstract
0
Cancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesMedicineBreast cancerOncologyMetastatic breast cancerInternal medicineCancerMale breast cancer
MeSH terms
Breast NeoplasmsFemaleHumansMaleRandomized Controlled Trials as TopicBreast Neoplasms, MaleObservational Studies as Topic
Citations
2,058
FWCI
81.80
field-weighted impact
References
202
Percentile
100%
vs. same field & year
Citations per year
Cited by
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Cancers · 2020 · 498 citations
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Annals of Oncology · 2018 · 1,168 citations
Male breast cancer: a disease distinct from female breast cancer
Breast Cancer Research and Treatment · 2018 · 372 citations
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Annals of Oncology · 2021 · 1,287 citations
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Annals of Oncology · 2020 · 1,319 citations
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Breast Cancer Research and Treatment · 2019 · 426 citations
References
Liquid Biopsies: Genotyping Circulating Tumor DNA
Journal of Clinical Oncology · 2014 · 2,169 citations
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
CHEST Journal · 2006 · 1,224 citations
Information needs of patients with cancer: results from a large study in UK cancer centres
British Journal of Cancer · 2001 · 854 citations
Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System
International Journal of Radiation Oncology*Biology*Physics · 2010 · 712 citations
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
The Lancet Oncology · 2014 · 1,891 citations
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
The Lancet Oncology · 2016 · 1,795 citations
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Annals of Oncology · 2018 · 853 citations
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians · 2018 · 87,314 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.